Resolution of cervical dysplasia is associated with T-cell proliferative responses to human papillomavirus type 16 E2

Journal of General Virology

Volumn 88, Issue 3, 2007, Pages 803-813

  Dillon, Stephanie ^a   Sasagawa, Toshiyuki ^b   Crawford, Anna ^a   Prestidge, Jan ^a   Inder, Marie K ^a   Jerram, Jim ^a   Mercer, Andrew A ^a   Hibma, Merilyn ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN E1; GLYCOPROTEIN E2; HISTIDINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; WART VIRUS VACCINE;

ADULT; ANTIBODY RESPONSE; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG RESPONSE; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; REMISSION; TH1 CELL; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DYSPLASIA; VIRUS LIKE AGENT;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CAPSID PROTEINS; CELL PROLIFERATION; DNA-BINDING PROTEINS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERFERON TYPE II; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; T-LYMPHOCYTES; UTERINE CERVICAL DYSPLASIA;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; PAPILLOMAVIRIDAE;

EID: 33847671483     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.82678-0     Document Type: Article

References (60)

1. Amelia, C. A., Lofgren, L. A., Ronn, A. M., Nouri, M., Shikowitz, M. J. & Steinberg, B. M. (1994). Latent infection induced with cottontail rabbit papillomavirus. A model for human papillomavirus latency. Am J Pathol 144, 1167-1171.
2. + T-cells: the holy grail?. Clin Exp Immunol 138, 10-13.
3. + T-cell response in HIV infection. AIDS Rev 6, 79-88.
4. Bontkes, H. J., de Gruijl, T. D., Bijl, A., Verheijen, R. H., Meijer, C. J., Scheper, R. J., Stern, P. L., Burns, J. E., Maitland, N. J. & Walboomers, J. M. (1999a). Human papillomavirus type 16 E2-specific T-helper lymphocyte responses in patients with cervical intraepithelial neoplasia. J Gen Virol 80, 2453-2459.
5. Bontkes, H. J., de Gruijl, T. D., Walboomers, J. M., Schiller, J. T., Dillner, J., Helmerhorst, T. J., Verheijen, R. H., Scheper, R. J. & Meijer, C. J. (1999b). Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16. J Gen Virol 80, 409-417.
6. Brown, D. M., Roman, E. & Swain, S. L. (2004). CD4 T cell responses to influenza infection. Semin Immunol 16, 171-177.
7. Chiang, C. M., Ustav, M., Stenlund, A., Ho, T. F., Broker, T. R. & Chow, L. T. (1992). Viral E1 and E2 proteins support replication of homologous and heterologous papillomaviral origins. Proc Natl Acad Sci U S A 89, 5799-5803.
8. Clerici, M., Merola, M., Ferrario, E., Trabattoni, D., Villa, M. L., Stefanon, B., Venzon, D. J., Shearer, G. M., De Palo, G. & Clerici, E. (1997). Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst 89, 245-250.
9. Clifford, G. M., Smith, J. S., Plummer, M., Muñoz, N. & Franceschi, S. (2003). Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88, 63-73.
10. Coleman, N., Birley, H. D., Renton, A. M., Hanna, N. F., Ryait, B. K., Byrne, M., Taylor-Robinson, D. & Stanley, M. A. (1994). Immunological events in regressing genital warts. Am J Clin Pathol 102, 768-774.
11. Conley, L. J., Ellerbrock, T. V., Bush, T. J., Chiasson, M. A., Sawo, D. & Wright, T. C. (2002). HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet 359, 108-113.
12. Davidson, E. J., Brown, M. D., Burt, D. J., Parish, J. L., Gaston, K., Kitchener, H. C., Stacey, S. N. & Stern, P. L. (2001). Human T cell responses to HPV 16 E2 generated with monocyte-derived dendritic cells. Int J Cancer 94, 807-812.
13. Davidson, E. J., Sehr, P., Faulkner, R. L., Parish, J. L., Gaston, K., Moore, R. A., Pawlita, M., Kitchener, H. C. & Stern, P. L. (2003). Human papillomavirus type 16 E2- and L1-specific serological and T-cell responses in women with vulval intraepithelial neoplasia. J Gen Virol 84, 2089-2097.
14. de Jong, A., van der Burg, S. H., Kwappenberg, K. M., van der Hulst, J. M., Franken, K. L., Geluk, A., van Meijgaarden, K. E., Drijfhout J. W. & Kanter, G. (2002). Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 62, 472-479.
15. + T-cell immunity against early antigens E2 and E6. Cancer Res 64, 5449-5455.
16. Ferenczy, A., Mitao, M., Nagai, N., Silverstein, S. J. & Crum, C. P. (1985). Latent papillomavirus and recurring genital warts. N Engl J Med 313, 784-788.
17. Filippova, M., Parkhurst, L. & Duerksen-Hughes, P. J. (2004). The human papillomavirus 16 E6 protein binds to Fas-associated death domain and protects cells from Fas-triggered apoptosis. J Biol Chem 279, 25729-25744.
18. Frazer, I. H. (2004). Prevention of cervical cancer through papilloma-virus vaccination. Nat Rev Immunol 4, 46-54.
19. Giroglou, T., Sapp, M., Lane, C., Fligge, C., Christensen, N. D., Streeck, R. E. & Rose, R. C. (2001). Immunological analyses of human papillomavirus capsids. Vaccine 19, 1783-1793.
20. Heard, I., Tassie, J. M., Schmitz, V., Mandelbrot, L., Kazatchkine, M. D. & Orth, G. (2000). Increased risk of cervical disease among human immunodeficiency virus-infected women with severe immunosuppression and high human papillamavirus load. Obstet Gynecol 96, 403-409.
21. Heinemann, L., Dillon, S., Crawford, A., Backstrom, B. T. & Hibma, M. H. (2004). Flow cytometric quantitation of the protective efficacy of dendritic cell based vaccines in a human papillomavirus type 16 murine challenge model. J Virol Methods 117, 9-18.
22. Hilders, C. G., Houbiers, J. G., Krul, E. J. & Fleuren, G. J. (1994). The expression of histocompatibility-related leukocyte antigens in the pathway to cervical carcinoma. Am J Clin Pathol 101, 5-12.
23. Hilders, C. G., Munoz, I. M., Nooyen, Y. & Fleuren, G. J. (1995). Altered HLA expression by metastatic cervical carcinoma cells as a factor in impaired immune surveillance. Gynecol Oncol 57, 366-375.
24. Jeon, S., Allen-Hoffmann, B. L. & Lambert P. F. (1995). Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J Virol 69, 2989-2997.
25. Johnston, K. B., Monteiro, J. M., Schultz, L. D., Chen, L., Wang, F., Ausensi, V. A., Dell, E. C., Santos, E. B., Moore, R. A. & other authors (2005). Protection of beagle dogs from mucosal challenge with canine oral papillomavirus by immunization with recombinant adenoviruses expressing codon-optimized early genes. Virology 336, 208-218.
26. Kadish, A. S., Timmins, P., Wang, Y., Ho, G. Y., Burk, R. D., Katz, J., He, W., Romney, S. L., Johnson, A. & other authors (2002). Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol Biomarkers Prev 11, 483-488.
27. Kirnbauer, R., Hubbert, N. L., Wheeler, C. M., Becker, T. M., Lowy, D. R. & Schiller, J. T. (1994). A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 86, 494-499.
28. Knowles, G., O'Neil, B. W. & Campo, M. S. (1996). Phenotypical characterization of lymphocytes infiltrating regressing papillomas. J Virol 70, 8451-8458.
29. Konya, J., Eklund, C., af Geijersstam, V., Yuan, F., Stuber, G. & Dillner, J. (1997). Identification of a cytotoxic T-lymphocyte epitope in the human papillomavirus type 16 E2 protein. J Gen Virol 78, 2615-2620.
30. Koutsky, L. A., Ault K. A., Wheeler, C. M., Brown, D. R., Barr, E., Alvarez, F. B., Chiacchierini, L. M. & Jansen, K. U. (2002). A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347, 1645--1651.
31. Lehtinen, M., Hibma, M. H., Stellato, G., Kuoppala, T. & Paavonen, J. (1995). Human T helper cell epitopes overlap B cell and putative cytotoxic T cell epitopes in the E2 protein of human papillomavirus type 16. Biochem Biophys Res Commun 209, 541-546.
32. Middleton, K., Peh, W., Southern, S., Griffin, H., Sotlar, K., Nakahara, T., El-Sherif, A., Morris, L., Seth, R. & other authors (2003). Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers. J Virol 77, 10186-10201.
33. Milde-Langosch, K., Riethdorf, S. & Loning, T. (2000). Association of human papillomavirus infection with carcinoma of the cervix uteri and its precursor lesions: theoretical and practical implications. Virchows Arch 437, 227-233.
34. + human CTL clones induced by candidate AIDS vaccines. J Immunol 153, 2787-2799.
35. + T-cell immunity to cytomegalo-virus. Hum Immunol 65, 456-464.
36. Muñoz, N., Bosch, F. X., de Sanjosé, S., Herrero, R., Castelisagué, X., Shah, K. V., Snijders, P. J. & Meijer, C. J. (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348, 518-527.
37. Nicholls, P. K., Doorbar, J., Moore, R. A., Peh, W., Anderson, D. M. & Stanley, M. A. (2001). Detection of viral DNA and E4 protein in basal keratinocytes of experimental canine oral papillomavirus lesions. Virology 284, 82-98.
38. + Th1 cells kill Burkitt's lymphoma cells. J Immunol 169, 1593-1603.
39. Petry, K. U., Scheffel, D., Bode, U., Gabrysiak, T., Kochel, H., Kupsch, E., Glaubitz, M., Niesert, S., Kuhnle, H. & Schedel, I. (1994). Cellular immunodeficiency enhances the progression of human papilloma-virus-associated cervical lesions. Int J Cancer 57, 836-840.
40. Pisani, P., Parkin, D. M. & Ferlay, J. (1993). Estimates of the world-wide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 55, 891-903.
41. Qian, J., Dong, Y., Pang, Y. Y., Ibrahim, R., Berzofsky, J. A., Schiller, J. T. & Khleif, S. N. (2006). Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice. Int J Cancer 118, 3022-3029.
42. Rose, R. C., Bonnez, W., Da Rin, C., McCance, D. J. & Reichman, R. C. (1994). Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles. J Gen Virol 75, 2445-2449.
43. Rudlinger, R., Smith, I. W., Bunney, M. H. & Hunter, J. A. (1986). Human papillomavirus infections in a group of renal transplant recipients. Br J Dermatol 115, 681-692.
44. Sarkar, A. K., Tortolero-Luna, G., Follen, M. & Sastry, K. J. (2005). Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV - 16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study. Gynecol Oncol 99, S251-S261.
45. Sasagawa, T., Rose, R. C., Azar, K. K., Sakai, A. & Inoue, M. (2003). Mucosal immunoglobulin-A and -G responses to oncogenic human papilloma virus capsids. Int J Cancer 104, 328-335.
46. Schiffman, M., Herrero, R., Desalle, R., Hildesheim, A., Wacholder, S., Rodriguez, A. C., Bratti, M. C., Sherman, M. E., Morales, J. & other authors (2005). The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 337, 76-84.
47. Schlecht N. F., Platt, R. W., Duarte-Franco, E., Costa, M. C., Sobrinho, J. P., Prado, J. C., Ferenczy, A., Rohan, T. E., Villa, L. L. & Franco, E. L. (2003). Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 95, 1336-1343.
48. Selvakumar, R., Ahmed, R. & Wettstein, F. O. (1995a). Tumor regression is associated with a specific immune response to the E2 protein of cottontail rabbit papillomavirus. Virology 208, 298-302.
49. Selvakumar, R., Borenstein, L. A., Lin, Y. L., Ahmed, R. & Wettstein, F. O. (1995b). Immunization with nonstructural proteins E1 and E2 of cottontail rabbit papillomavirus stimulates regression of virus-induced papillomas. J Virol 69, 602-605.
50. Sun, Y., Eluf-Neto, J., Bosch, F. X., Muñoz, N., Walboomers, J. M., Meijer, C. J., Shah, K. V., Clayman, B. & Viscidi, R. P. (11999). Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma. Cancer Epidemiol Biomarkers Prev 8, 935-940.
51. Tagami, H., Oguchi, M. & Ofuji, S. (1980). The phenomenon of spontaneous regression of numerous flat warts: immunohistological studies. Cancer 45, 2557-2563.
52. Thompson, D. A., Zacny, V., Belinsky, G. S., Classon, M., Jones, D. L., Schlegel, R. & Münger, K. (2001). The HPV E7 oncoprotein inhibits tumor necrosis factor α-mediated apoptosis in normal human fibroblasts. Oncogene 20, 3629-3640.
53. Vambutas, A., DeVoti, J., Pinn, W., Steinberg, B. M. & Bonagura, V. R. (2001). Interaction of human papillomavirus type 11 E7 protein with TAP-1 results in the reduction of ATP-dependent peptide transport. Clin Immunol 101, 94-99.
54. van Poelgeest, M. I., Nijhuis, E. R., Kwappenberg, K. M., Hamming, I. E., Wouter Drijfhout, J., Fleuren, G. J., van der Zee, A. G., Melief, C. J., Kanter, G. G. & other authors (2006). Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia. Int J Cancer 118, 675-683.
55. Vayrynen, M., Syrjanen, K., Mantyjarvi, R., Castren, O. & Saarikoski, S. (1984). Langerhans cells in human papillomavirus (HPV) lesions of the uterine cervix identified by the monoclonal antibody OKT-6. Int J Gynaecol Obstet 22, 375-383.
56. Vayrynen, M., Syrjanen, K., Mantyjarvi, R., Castren, O. & Saarikoski, S. (1985). Immunophenotypes of lymphocytes in prospectively followed up human papillomavirus lesions of the cervix. Genitourin Med 61, 190-196.
57. Viscidi, R. P., Schiffman, M., Hildesheim, A., Herrero, R., Castle, P. E., Bratti, M. C., Rodriguez, A. C., Sherman, M. E. & Wang, S. (2004). Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 13, 324-327.
58. Walboomers, J. M., Jacobs, M. V., Manos, M. M., Bosch, F. X., Kummer, J. A., Shah, K. V., Snijders, P. J., Peto, J., Meijer, C. J. & Muñoz, N. (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189, 12-19.
59. Wick M. J. & Pfeifer, J. D. (1996). Major histocompatibility complex class I presentation of ovalbumin peptide 257-264 from exogenous sources: protein context influences the degree of TAP-independent presentation. Eur J Immunol 26, 2790-2799.
60. Zagury, D. (1991). Anti-HIV cellular immunotherapy in AIDS. Lancet 338, 694-695.